Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BTCY 
Biotricity Inc (BTCY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/16/2025: BTCY (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -25.37% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.43M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 1 | Beta 1.23 | 52 Weeks Range 0.19 - 0.89 | Updated Date 07/17/2025 |
52 Weeks Range 0.19 - 0.89 | Updated Date 07/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.61 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -80.42% | Operating Margin (TTM) -4.67% |
Management Effectiveness
Return on Assets (TTM) -50.53% | Return on Equity (TTM) -4100.79% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 37292681 | Price to Sales(TTM) 0.71 |
Enterprise Value 37292681 | Price to Sales(TTM) 0.71 | ||
Enterprise Value to Revenue 2.81 | Enterprise Value to EBITDA -3.76 | Shares Outstanding 24751800 | Shares Floating 17123308 |
Shares Outstanding 24751800 | Shares Floating 17123308 | ||
Percent Insiders 40.3 | Percent Institutions 2.69 |
Upturn AI SWOT
Biotricity Inc
Company Overview
History and Background
Biotricity Inc. was founded in 2012. It focuses on developing and marketing medical-grade wearable biosensors and remote patient monitoring solutions. The company aims to provide solutions for chronic disease management and early detection of health conditions.
Core Business Areas
- Remote Patient Monitoring (RPM) Solutions: Provides a platform that enables healthcare providers to remotely monitor patients' vital signs and health conditions. Key offering is Bioflux, which is a wearable device for cardiac monitoring.
Leadership and Structure
The leadership team includes Waqaas Al-Siddiq, Founder & CEO. The company operates with a structure typical of a development-stage medical device company.
Top Products and Market Share
Key Offerings
- Bioflux: Bioflux is a mobile cardiac telemetry (MCT) system used for cardiac monitoring. Market share data is not readily available as Biotricity competes with larger, established players. Key competitors are iRhythm Technologies (IRTC) and Preventice Solutions (acquired by Boston Scientific).
Market Dynamics
Industry Overview
The remote patient monitoring (RPM) market is experiencing significant growth due to increasing prevalence of chronic diseases, aging population, and advancements in technology. The market is competitive and regulated.
Positioning
Biotricity is positioned as a provider of medical-grade wearable biosensors and remote patient monitoring solutions, targeting healthcare providers and patients. They compete in a market dominated by larger, more established companies.
Total Addressable Market (TAM)
The global remote patient monitoring market is expected to reach billions of dollars. Biotricity, as a smaller player, aims to capture a portion of this market by offering specialized cardiac monitoring solutions. Actual figures vary, but market forecasts are readily available from industry research firms.
Upturn SWOT Analysis
Strengths
- Medical-grade wearable technology
- Focus on cardiac monitoring
- Remote patient monitoring platform
Weaknesses
- Limited financial resources
- Smaller market share compared to competitors
- Dependence on regulatory approvals
- Limited brand recognition
Opportunities
- Growing remote patient monitoring market
- Partnerships with healthcare providers
- Expansion into new chronic disease areas
- Technological advancements in wearable sensors
Threats
- Competition from larger, established companies
- Regulatory changes
- Technological obsolescence
- Reimbursement challenges from payers
Competitors and Market Share
Key Competitors
- IRTC
- BSX
Competitive Landscape
Biotricity faces intense competition from larger companies with more resources. Its competitive advantage lies in its specialized cardiac monitoring solutions and remote patient monitoring platform, but it needs to scale sales and marketing efforts to gain significant market share.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been moderate, tied to product development and regulatory milestones.
Future Projections: Future growth is contingent on increasing sales of its Bioflux system and expanding its remote patient monitoring platform. Analyst estimates vary depending on market conditions and the company's execution.
Recent Initiatives: Recent initiatives include securing regulatory approvals, expanding its sales force, and forming partnerships with healthcare providers.
Summary
Biotricity Inc. is a small player in the remote patient monitoring market with potential for growth in cardiac monitoring. It faces tough competition, and its success hinges on its ability to execute its sales strategy, gain regulatory approvals, and secure financing. The company's strengths are its medical-grade technology, but it must address its limited financial resources and brand recognition. Investors should monitor its progress closely in a highly competitive industry.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and may vary. Consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biotricity Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2016-02-18 | Founder, President, CEO & Chairman Dr. Waqaas Al-Siddiq Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 55 | Website https://www.biotricity.com |
Full time employees 55 | Website https://www.biotricity.com | ||
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. Biotricity, Inc. is based in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.